Gene Therapies for Neurological Diseases
The report explores how leading developers, emerging technologies, and strategic collaborations are shaping the next generation of therapies capable of addressing complex central nervous system (CNS) disorders. From AI-engineered AAV capsids to epigenetic editing platforms and non-viral delivery systems, it provides a detailed analysis of where innovation and investment are accelerating. Whether your focus is scientific advancement, market positioning, or partnership strategy, this report offers the intelligence you need to stay ahead in neurological gene therapy.
Key insights:
- Comprehensive landscape overview: 832 active assets targeting neurological disorders, accounting for 24.7% of all gene therapy programs tracked globally.
- Clinical momentum: 29 new trials and 22 new drug programs.
- Technology innovation: In-depth analysis of AAV9 and next-generation capsids, non-viral delivery platforms, and gene editing advancements including CRISPR and epigenetic systems.
- Market and partnership activity: Latest deals, collaborations, and restructuring moves from leading developers such as Sarepta, Regenxbio, Roche, and AbbVie.
- Future outlook: Emerging technologies and assets to watch – and how they’re poised to transform the treatment landscape for neurological diseases.
You May Also Be Interested In…
Learn More About Gene Therapy
- The Most Comprehensive Way to Search the Gene Therapy Development Landscape: Unique search ontologies based on Gene Therapy drug and trial characteristics
- Market Leading Approach to Gene Therapy Preclinical & Clinical Data Curation: Manual curation of key Gene Therapy research and development data points by Gene Therapy research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Gene Therapy company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
